Omar Ibrahim

Omar Ibrahim

Auto-generated profile, based on publicly available information

Omar Ibrahim

Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2020 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
SLSunghee Lee
Sunghee Lee
CWConnor N. Woods
Connor N. Woods
OIOmar Ibrahim
Omar Ibrahim
SKSung Wook Kim
Sung Wook Kim
SPSeung Beom Pyun
Seung Beom Pyun
SPSo-Jung Park
So-Jung Park

21 January 2022 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
CBCéline Burel
Céline Burel
OIOmar Ibrahim
Omar Ibrahim
EMEmanuele Marino
Emanuele Marino
HBHarshit Bharti
Harshit Bharti
CMChristopher B. Murray
Christopher B. Murray
RDRémi Dreyfus
Rémi Dreyfus

27 July 2021 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
OIOmar Ibrahim
Omar Ibrahim
SLSunghee Lee
Sunghee Lee
SKSung Wook Kim
Sung Wook Kim
SPSeung Beom Pyun
Seung Beom Pyun
CWConnor Woods
Connor Woods
ZFZahra Fakhraai
Zahra Fakhraai

8 April 2022 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
SLSunghee Lee
Sunghee Lee
OIOmar Ibrahim
Omar Ibrahim
ZFZahra Fakhraai
Zahra Fakhraai
SPSo-Jung Park
So-Jung Park

21 February 2026 in Radiology Case Reports
Verified
Journal Article
Open access
OIOmar Ibrahim
Omar Ibrahim
NCNicholas S Cho
Nicholas S Cho
VLViên Lam Le
Viên Lam Le
FSFrancesco Sanvito
Francesco Sanvito
JYJingwen Yao
Jingwen Yao
BEBenjamin M. Ellingson
Benjamin M. Ellingson
We present a rare case of concurrent, spatially distinct 1p/19q-intact IDH-mutant astrocytoma and 1p/19q-codeleted IDH-mutant oligodendroglioma in the same patient with divergent responses to IDH inhibitor therapy. A 40-year-old male presented to the emergency room following a seizure and was found to have 2 distinct left hemisphere tumors. Both lesions underwent biopsy and resection, with updated molecular diagnosis 4 years later revealing IDH-mutant 1p/19q-intact astrocytoma and IDH-mutant 1p/19q-codeleted oligodendroglioma. Tumor volumes, T2-FLAIR mismatch percentage, and normalized apparent diffusion coefficient (nADC) were quantified from serial MRIs. At initial presentation, quantitative analysis revealed the posterior lesion (IDH-mutant 1p/19q-intact astrocytoma) exhibited 60.6% T2-FLAIR mismatch volume and elevated median nADC of 2.72, while the anterior lesion (IDH-mutant 1p/19q-codeleted oligodendroglioma) showed minimal T2-FLAIR mismatch (1.8%) and lower median nADC (1.94). Volumetric analysis during IDH inhibitor (ivosidenib) therapy revealed differential response: the oligodendroglioma decreased in volume by 32.6% over 19 months, while the astrocytoma demonstrated progressive growth with a 77.3% volume increase over 19 months. This case demonstrates the utility of quantitative neuroimaging for accurate characterization of concurrent IDH-mutant gliomas with distinct molecular profiles. The observed differential response to IDH inhibition supports emerging evidence of molecular subtype-specific treatment sensitivities in IDH-mutant gliomas.